Two substances belonging to a new class have recently been approved in Switzerland for the non-hormonal treatment of menopausal hot flashes. This changes the way patients are counseled, but it does not render the rest of the treatment spectrum obsolete, nor does it override the rule stated at the beginning of the Swiss expert letter on the subject: A significant reduction in hot flashes is not synonymous with freedom from symptoms [1].
Autoren
- Jens Dehn
Publikation
- GYNÄKOLOGIE PRAXIS
Related Topics
You May Also Like
- Cardiology and Nutrition
Ultra-Processed Foods and Cardiovascular Risk—The New AHA Position Statement
- The Brain and the Motivation to Eat
Why is it so hard to lose weight?
- Breast (HR+) and Endometrial Cancer
A Comparison of Hormone-Dependent Female Tumors
- Chronic Urticaria: Treatment for Patients Unresponsive to Antihistamines
In addition to anti-IgE antibodies, the guideline recommends anti-IL-4α antibodies and BTK inhibition
- Type 1 Diabetes in Childhood
Early Impairment of Glucagon Counterregulation
- Psychosis in Parkinson's Disease
Be Careful When Choosing Medications
- Esophageal Cancer
A Comparison of Endoscopic and Surgical Innovations
- PMR and LVV: Current EULAR Recommendations